A型肉毒毒素B治疗喉肌张力障碍：范围综述

文献信息

中文摘要

目的： 我们旨在全面梳理关于A型肉毒毒素B（BoNT-B）治疗喉肌张力障碍的现有文献。
数据来源： 使用图书馆员设计的综合检索策略，检索EMBASE、MEDLINE和Web of Science中从数据库建库至2025年12月的英文研究。
综述方法： 一项PRISMA-ScR范围综述已在Open Science Framework注册（10.23041/OSF.IJ/R3BG4）。由两名研究者独立进行文献筛选，纳入所有关于成人患者接受BoNT-B治疗喉肌张力障碍的英文研究。分析BoNT-B治疗剂量、治疗结局（即声音中断/音量、痉挛）、患者报告结局测量（PROMs）以及不良治疗事件（即气息声/呼吸困难、吞咽困难）。使用ROBINS-I V2工具评估偏倚风险。
结果： 数据库检索共识别出188项研究，其中4项研究在全文审阅后符合纳入标准。两项研究为临床队列研究，两项为病例报告。所有研究纳入的参与者总数为47例，其中46例诊断为内收型喉肌张力障碍。纳入研究的注射剂量方案范围为50-750单位。肉毒毒素治疗结局报告大多为主观性，但显示BoNT-B注射有效。没有研究评估BoNT-B治疗喉肌张力障碍的标准化PROMs。所有纳入研究中均未描述严重不良事件。所有纳入研究的偏倚风险评分均为“严重”。
结论： 本研究发现了文献中的空白，建议对BoNT-B治疗喉肌张力障碍进行客观临床评估。

英文摘要

OBJECTIVES: We aimed to comprehensively map the available literature on botulinum toxin B (BoNT-B) for the treatment of laryngeal dystonia.
DATA SOURCES: A comprehensive librarian-designed strategy was used to search EMBASE, MEDLINE, and Web of Science for English-language studies from database inception to December 2025.
REVIEW METHODS: A PRISMA-ScR scoping review was registered on Open Science Framework (10.23041/OSF.IJ/R3BG4). Study selection was independently performed by two investigators for all English-language studies of adult patients investigating BoNT-B treatment for laryngeal dystonia. BoNT-B treatment dosing, treatment outcomes (ie, voice breaks/volume, spasms), patient-reported outcomes measures (PROMs), and adverse treatment events (ie, breathiness/dyspnea, dysphagia) were analyzed. Risk of bias was assessed with the ROBINS-I V2 tool.
RESULTS: In total, 188 studies were identified through the database searches, of which four studies met the inclusion criteria following full manuscript review. Two studies were clinical cohort studies in nature, and two were case reports. The total number of participants included in all studies was 47, of which 46 were diagnosed with adductor laryngeal dystonia. Injection dosing regimen ranged from 50-750 units among the included studies. Botulinum toxin treatment outcome reporting was largely subjective but demonstrated efficacy of BoNT-B injection. No study evaluated standardized PROMs in BoNT-B treatment of laryngeal dystonia. No serious adverse events were described among all included studies. Risk of bias was scored as "Serious" for all included studies.
CONCLUSION: The current study identified a gap within the literature recommending objective clinical evaluation of BoNT-B for the treatment of laryngeal dystonia.